Sinocelltech Group
Sinocelltech Group Ltd is a Chinese biopharmaceutical company developing recombinant proteins, monoclonal antibodies, and vaccines. The company researches, produces, and commercializes biologic candidates, highlighted by its recombinant human coagulation factor VIII (Anjiavin) for hemophilia A, alongside anti-PD-1 antibodies and COVID-19 vaccine candidates. Main revenue drivers comprise commercial sales of recombinant coagulation factor products, biopharmaceutical milestone payments, and research grants. Sinocelltech Group serves hematologists, hospital networks, prescription pharmacies, and hemophilia patients across China. The company holds an innovative market position in China as a pioneer in domestic recombinant coagulation factor production and biological therapeutic development. Headquartered in Beijing, China, it is listed on the STAR Market of the Shanghai Stock Exchange.
2 of the funds FundTelligence covers report a position in Sinocelltech Group.
- Legal name
- Sinocelltech Group Ltd
- Sector
- Health Care
- Country
- China
- Funds holding it
- 2
Funds holding Sinocelltech Group
- Handelsbanken Emerging Markets Index — Handelsbanken · 0.0 % (full portfolio disclosed, September 2026)
- Handelsbanken Global Index Criteria — Handelsbanken · 0.0 % (full portfolio disclosed, September 2026)